Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).

In Uganda, the HIV Network for Prevention Trials (HIVNET) 012 study recently demonstrated that single-dose nevirapine (Nvp) prophylaxis is effective for preventing mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1). This exploratory study examines the relationship between HIV-1 subtype, MTCT, and the development of Nvp resistance (Nvp(R)) in women enrolled in HIVNET 012. For 102 women (32 whose infants were HIV-1 infected by age 6-8 weeks and 70 whose infants were uninfected), HIV-1 subtypes included 50 (49%) subtype A, 35 (34%) subtype D, 4 (4%) subtype C, 12 (12%) recombinant subtype, and 1 unclassified. There was no apparent difference in the rate of MTCT among women with subtype A versus D (adjusted odds ratio [OR], 1.24; 95% confidence interval [CI], 0.45-3.43). Nvp(R) mutations were detected more frequently at 6-8 weeks postpartum in women with subtype D than in women with subtype A (adjusted OR, 4.94; 95% CI, 1.21-20.22). Additional studies are needed to further define the relationship between HIV-1 subtype and Nvp(R) among women receiving Nvp prophylaxis.

[1]  Dorothy Bray,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial , 1999, The Lancet.

[2]  Roderic D. M. Page,et al.  TreeView: an application to display phylogenetic trees on personal computers , 1996, Comput. Appl. Biosci..

[3]  L. Mofenson,et al.  Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) , 2001, AIDS.

[4]  P. Kaleebu,et al.  Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort , 2001, AIDS.

[5]  J. Giesecke,et al.  Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. , 1999, AIDS.

[6]  S. Eshleman,et al.  Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults. , 2000, AIDS research and human retroviruses.

[7]  L. Guay,et al.  Identification of diverse HIV type 1 subtypes and dual HIV type 1 infection in pregnant Ugandan women. , 2000, AIDS research and human retroviruses.

[8]  F. Plummer,et al.  Effect of human immunodeficiency virus (HIV) type 1 viral genotype on mother-to-child transmission of HIV-1. , 2000, The Journal of infectious diseases.

[9]  D. Pieniążek,et al.  Predominance of HIV-1 subtype A and D infections in Uganda. , 2000, Emerging infectious diseases.

[10]  C. Luo,et al.  A molecular epidemiologic survey of HIV in Uganda , 1998, AIDS.

[11]  I. Thior,et al.  Human immunodeficiency virus type 1 subtypes differ in disease progression. , 1999, The Journal of infectious diseases.

[12]  L. Guay,et al.  Dual transmission of subtype A and D HIV type 1 viruses from a Ugandan woman to her infant. , 1999, AIDS research and human retroviruses.